9月1日晚间,先声药业集团有限公司(以下简称“先声药业”)公告称,已与罗氏(Roche)就CD79a/CD19/CD3三特异性抗体SIM0660达成全球开发和商业化合作。 根据协议条款,罗氏将获得SIM0660在全球范围内的独家开发、生产与商业化权益。先声药业将有资格收取最高可达15.30亿美元的总交易付款,其中包括7500万美元首付款。基于未来净销售额,先声药业亦可能有权收取最高至双位数的分级...
Source Link9月1日晚间,先声药业集团有限公司(以下简称“先声药业”)公告称,已与罗氏(Roche)就CD79a/CD19/CD3三特异性抗体SIM0660达成全球开发和商业化合作。 根据协议条款,罗氏将获得SIM0660在全球范围内的独家开发、生产与商业化权益。先声药业将有资格收取最高可达15.30亿美元的总交易付款,其中包括7500万美元首付款。基于未来净销售额,先声药业亦可能有权收取最高至双位数的分级...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.